John W. Kozarich net worth and biography

John Kozarich Biography and Net Worth

Director of Ligand Pharmaceuticals

John W. Kozarich, Ph.D., has served as a member of our board since March 2003. Since November 2019, Dr. Kozarich has served as interim Chief Executive Officer of Curza Global, LLC, a biopharmaceutical company, where he has served as a member of the board of directors since February 2019. Dr. Kozarich also serves as Distinguished Scientist Emeritus of ActivX Biosciences, Inc., and previously served as ActivX’s Chairman and President from 2004 through March 2017. From 1992 to 2001, Dr. Kozarich was vice president at Merck Research Laboratories and previously held professorships at the University of Maryland and Yale University School of Medicine. Dr. Kozarich is also an adjunct professor of Chemical Biology and Medicinal Chemistry at the University of Texas, Austin and serves on the board of Intec Pharma Ltd., a publicly-traded biotechnology company. Previously, Dr. Kozarich served as a director of ActivX Biosciences Inc., Corium Intl, Novelion Therapeutics and Retrophin, Inc. He is also a recipient of the Distinguished Scientist Award from the San Diego Section of the American Chemical Society. Dr. Kozarich earned his B.S. in chemistry, summa cum laude, from Boston College, his Ph.D. in biological chemistry from the Massachusetts Institute of Technology, and was an NIH Postdoctoral Fellow at Harvard.

What is John W. Kozarich's net worth?: The estimated net worth of John W. Kozarich is at least $8.32 million as of December 1st, 2025. Dr. Kozarich owns 44,121 shares of Ligand Pharmaceuticals stock worth more than $8,316,809 as of December 4th. This net worth approximation does not reflect any other assets that Dr. Kozarich may own. Learn More about John W. Kozarich's net worth.
How do I contact John W. Kozarich?: The corporate mailing address for Dr. Kozarich and other Ligand Pharmaceuticals executives is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. Ligand Pharmaceuticals can also be reached via phone at (858) 550-7500 and via email at [email protected]. Learn More on John W. Kozarich's contact information.
Has John W. Kozarich been buying or selling shares of Ligand Pharmaceuticals?: Within the last three months, John W. Kozarich has sold $264,476.11 in shares of Ligand Pharmaceuticals stock. Most recently, John W. Kozarich sold 467 shares of the business's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $195.84, for a transaction totalling $91,457.28. Following the completion of the sale, the director now directly owns 44,121 shares of the company's stock, valued at $8,640,656.64. Learn More on John W. Kozarich's trading history.
Who are Ligand Pharmaceuticals' active insiders?: Ligand Pharmaceuticals' insider roster includes Todd Davis (CEO), Octavio Espinoza (CFO), Matthew Foehr (COO), Nancy Gray (Director), John Higgins (CEO), John Kozarich (Director), John LaMattina (Director), Andrew Reardon (Chief Legal Officer), and Stephen Sabba (Director). Learn More on Ligand Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ligand Pharmaceuticals?: During the last year, Ligand Pharmaceuticals insiders bought shares 2 times. They purchased a total of 11,010 shares worth more than $1,156,542.00. During the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 22,373 shares worth more than $3,264,991.97. The most recent insider tranaction occured on December, 1st when Director John W Kozarich sold 467 shares worth more than $91,457.28. Insiders at Ligand Pharmaceuticals own 7.0% of the company. Learn More about insider trades at Ligand Pharmaceuticals.
Information on this page was last updated on 12/1/2025.

John W. Kozarich Insider Trading History at Ligand Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/1/2025	Sell	467	$195.84	$91,457.28	44,121
11/3/2025	Sell	467	$191.05	$89,220.35	44,588
10/1/2025	Sell	467	$179.44	$83,798.48	45,055
9/2/2025	Sell	467	$162.26	$75,775.42	45,522
8/1/2025	Sell	467	$131.88	$61,587.96	45,989
7/10/2025	Sell	934	$125.00	$116,750.00	46,456
5/16/2023	Sell	4,444	$77.20	$343,076.80	38,488
5/8/2023	Sell	6,408	$76.56	$490,596.48	42,213
2/28/2022	Sell	908	$102.62	$93,178.96
10/1/2018	Sell	2,500	$275.04	$687,600.00	26,142
7/2/2018	Sell	2,500	$207.48	$518,700.00	28,642
4/2/2018	Sell	2,500	$160.43	$401,075.00
1/10/2018	Sell	2,500	$145.00	$362,500.00	33,149
11/16/2017	Sell	5,000	$141.71	$708,550.00	35,649
9/7/2016	Sell	1,000	$115.00	$115,000.00	39,983
9/1/2016	Sell	1,666	$105.40	$175,596.40	40,783
8/1/2016	Sell	1,000	$137.57	$137,570.00	41,783
7/1/2016	Sell	1,000	$121.40	$121,400.00	42,883
6/1/2016	Sell	1,000	$117.42	$117,420.00	43,361
5/2/2016	Sell	1,000	$121.57	$121,570.00	43,911
4/6/2016	Sell	5,000	$115.00	$575,000.00	44,711
1/20/2016	Sell	1,666	$94.94	$158,170.04	49,711
10/15/2014	Buy	2,000	$45.68	$91,360.00

John W. Kozarich Buying and Selling Activity at Ligand Pharmaceuticals

Ligand Pharmaceuticals Company Overview

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Today's Range

Now: $188.50

$187.87

$194.90

50 Day Range

MA: $191.39

$169.72

$209.29

2 Week Range

Now: $188.50

$93.58

$212.49

Volume

194,343 shs

Average Volume

226,796 shs

Market Capitalization

$3.71 billion

P/E Ratio

91.06

Dividend Yield

N/A

Beta

0.99